View
226
Download
0
Category
Preview:
Citation preview
8/11/2019 Helicobacter Pylori Journal Article
1/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print
www.medscape.com
Review Article
An Ecological Study
Abstract and Introduction
Abstract
Background. There is emerging debate over the effect of Helicobacter pyloriinfection on body mass index (BMI). A
recent study demonstrated that individuals who underwent H. pylorieradication developed significant weight gain as
compared to subjects with untreated H. pyloricolonisation.
Aim. To elucidate the association between H. pyloricolonisation and the prevalence of overweight and obesity in
developed countries.
Methods. The literature was searched for publications reporting data on H. pyloriprevalence rates and obesity
prevalence rates. Studies selected reported H. pyloriprevalence in random population samples with sample sizes of
more than 100 subjects in developed countries (GDP >25 000 US$/person/year). Corresponding BMI distributions for
corresponding countries and regions were identified. Nonparametric tests were used to compare the association
between H. pyloriand overweight and obesity rates.
Results. Forty-nine studies with data from 10 European countries, Japan, the US and Australia were identified. The
mean H. pylorirate was 44.1% (range 1775%), the mean rates for obesity and overweight were 46.6 (16)% and
14.2 (8.9)%. The rate of obesity and overweight were inversely and significantly (r= 0.29, P< 0.001) correlated with
the prevalence of H. pyloriinfection.
Conclusions. There is an inverse correlation between H. pyloriprevalence and rate of overweight/obesity in countries
of the developed world. Thus, the gradual decrease of the H. pyloricolonisation that has been observed in recent
decades (or factors associated with decrease of) could be causally related to the obesity endemic observed in the
Western world.
Introduction
In Western countries, the prevalence of those people classified as overweight (BMI >25 > 30) and obese (BMI >30)
has substantially increased.[1,2]The WHO in 2008 estimated that over 500 million adults have obesity, representing
1014% of the world's population. [2]In this context, there is emerging debate over the effect of Helicobacter pylori(H.pylori)infection on body mass index (BMI). While several cross-sectional studies have observed an association of H.
pyloriinfection with BMI,[3,4]the National Health and Nutrition Examination Survey (NHANES III) did not find an
association.[5]Other studies have evaluated the impact of H. pylorieradication on BMI. Kamada et al. demonstrated
that Japanese patients who underwent H. pylorieradication developed significant weight gain as compared to
subjects with untreated H. pyloricolonisation.[6]This has since been confirmed in a larger population-based
randomised controlled trial in England where people gained more than 3 kg of weight in the intervention (19%) as
compared to placebo (13%), although follow-up of this study was limited to 6 months. [7]In addition, animal studies
have shown that H. pyloricolonisation decreased fasting blood glucose levels, increased levels of leptin, improved
glucose tolerance, and suppressed weight gain.[8]All this may indeed suggest a role of the reduction of the H. pylori
Review Article: Associations Between Helicobacter PyloriandObesity - An Ecological Study
N. Lender, N. J. Talley, P. Enck, S. Haag, S. Zipfel, M. Morrison, G. J. Holtmann
Aliment Pharmacol Ther. 2014;40(1):24-31.
http://www.medscape.com/http://www.medscape.com/http://www.medscape.com/8/11/2019 Helicobacter Pylori Journal Article
2/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 2
prevalence as a contributing factor for the obesity endemic.
It is widely accepted that environmental factors such as the availability and the characteristics of food and dietary
habits[9]play a role, while there are also genetic factors [10]that influence the manifestation of obesity. On the other
hand, it is interesting to note that some cohort studies do not find an association between nutrition and obesity[11]
suggesting that factors other than caloric intake are important for the obesity endemic. Nevertheless, there are
overwhelming data supporting that the endemic of obese patients is linked to an increased incidence of cancer[12]
and liver disease.[13]
While the obesity epidemic has been observed for prolonged periods of time in the Western World, there is now
emerging evidence that the obesity epidemic is spreading to the developing world.[14]Interestingly, there is now a
substantial decrease in the H. pyloriprevalence. However, it is as yet unknown if on a larger scale (e.g. across
different populations and countries) there might be an association between H. pyloriand obesitas. In the Western
World, the prevalence of H. pyloriis decreasing.[15]H. pyloriinfection is prevalent worldwide, with a large disparity
between developed and developing countries.[2]This decreasing prevalence of H. pylorimay represent a risk or
contributing factor to the world-wide endemic of obesity with all its complications. However, as yet there are no
systematic analyses that aim to assess a potential association between the prevalence of H. pyloriand the
prevalence of obesity across various geographical regions of the world. Thus, this study aimed to elucidate the
potential link between H. pyloriand the prevalence of obesity and people who are overweight in developed countries.
Methods
Helicobacter PyloriPrevalence
The literature was searched for publications reporting H. pyloriprevalence rates between 1990 and 2012. Two
researchers (NL & GH) conducted searches independently. Literature keyword searches included 'Helicobacter pylori
and 'prevalence' and retrieved 6945 articles. This was narrowed down on the basis of the outlined inclusion and
exclusion criteria including adult population, random (population) samples of both gender, H. pyloriinfection assessed
via serology, urea breath test or stool samples and sample size >100 subjects. Studies focussing on nonrandom
samples or patient cohorts with H. pyloriassociated disease were excluded. In addition, only studies from countries
with a GDP >$ 25,000 were included. Based upon this, 196 publications were identified. Full text articles werereviewed to ensure that all inclusion and exclusion criteria were met. Finally, 50 studies with data from 10 European
countries, Japan, USA, Canada and Australia were identified that were suitable for further analysis ( ). WHO and
other databases were then searched for overweight and obesity prevalence rates. Data from the relevant countries and
years corresponding (5 years) with the H. pyloridata were selected ( ).
Table 1. Studies reporting of H. pyloriprevalence (proportion of subjects with H. pyloriinfection) and WHO data on body
mass index (proportion of overweight (BMI 2530) and obese (BMI >30) subjects in the various countries
Study
Sample
size Methods Country Year
Prevalence
H. pylori
Prevalence
overweight
Prevalence
obesity
Shapira et al.31 100 Serology Italy 2011 0.3 0.44 0.098
Peleteiro et al34 649 Serology Portugal 2011 0.85 0.535 0.142
Lane et al.7 10 537 UBT UK 2011 0.155 0.61 0.227
Adamu et al.33 5229 Serology Germany 2011 0.4984 0.665 0.129
Whiteman et
al.351346 Serology Australia 2010 0.23 0.49 0.164
Telaranta-Keerie 4256 Serology, Finland 2010 0.19 0.488 0.157
8/11/2019 Helicobacter Pylori Journal Article
3/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 3
et al.36 ELISA
Sasazuki et al.37 494 Serology Japan 2010 0.751 0.232 0.031
Salomaa-
Rasanen et al.38504 Serology Finland 1994 0.36 0.42 0.106
Risch et al.32 690 Serology;
ELISA
USA 2010 0.17391 0.669 0.339
Kawai et al.39 418 Serology,IgG
Japan 2010 0.337 0.232 0.031
Fullerton et al.40 2437 Serology England 2009 0.264 0.61 0.227
Moujaber et al.41 2413 Serology Australia 2002 0.151 0.462 0.151
De Bastiani et
al.43104 Urea breath
test
Italy 2008 0.54 0.44 0.098
Stettin et al.44 563 Stool
samples
Germany 2007 0.21 0.665 0.129
SanchezCeballos et al.45
481 Urea breathtest
Spain 2007 0.603 0.534 0.156
Naja et al.46 1306 Serology Canada 2007 0.231 0.591 0.231
Sharara et al.47 104
(males
only)
Serology Italy 2006 0.683 0.44 0.098
Macenlle Garcia
et al.48383 Urea breath
test
Spain 2006 0.691 0.534 0.156
Cardenas et al.49 7462 Serology USA 2000 0.271 0.583 0.307
Kuepper-Nybelen
et al.496545 Serology Germany 1999 0.407 0.60 0.203
Ioannou et al.26 3130 Serology USA 2005 0.35 0.669 0.339
Ang et al.50 595 Serology Japan 2005 0.463 0.325 0.069
Cho et al.5 7003 Serology USA 2005 0.38 0.669 0.339
Simon et al.51 6746 Serology USA 2003 0.32 0.545 0.307
Robertson et
al.52
500 Serology Australia 2003 0.32 0.49 0.164
Nishise et al.53 695 Serology Japan 2003 0.6 0.232 0.031
Iszlai et al.54 756 ELISA Hungary 2000 0.586 0.532 0.177
Moayyedi et
al.558429 13C urea
breath test
England 2002 0.276 0.61 0.227
Bode et al.56 474 Serology Germany 2001 0.308 0.606 0.194
Bazzoli et al.57 1533 13C Urea
breath test
Italy 2001 0.679 0.42 0.085
8/11/2019 Helicobacter Pylori Journal Article
4/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 4
Rosenstock et
al.582527 Serology Denmark 1983
1994
0.247 0.417 0.094
Everhart et al.59 5465 Serology USA 1988
1991
0.325 0.55 0.227
Russo et al.60 2598 Serology Italy 1995
1997
0.45 0.385 0.064
Peach et al.61 324 Serology Australia 1999 0.3 0.573 0.193
Collett et al.62 1060 Serology Australia 1999 0.24 0.573 0.193
Senra-Varel et
al.63332 Serology Spain 1998 0.43 0.36 0.121
Martin de Argila
et al.64301 Serology UK 1998 0.522 0.669 0.11
Lin et al.65 273 Serology Australia 1998 0.38 0.598 0.193
Dite et al.66 309 Serology Czech
republic
1998 0.588 0.46 0.114
Babus et al.67 456 Serology Croatia 1998 0.5105 0.644 0.231
Rodrigo Saez et
al.68480 Serology Spain 1997 0.492 0.488 0.121
Peach et al.61 217 Serology Australia 1995 0.306 0.573 0.193
Murray et al.69 4742 Serology Northern
Ireland
1997 0.505 0.669 0.11
Babus et al.70 3082 Serology Croatia 1997 0.604 0.644 0.231
Martin-de-Argila
et al.71381 Serology Spain 1996 0.53 0.488 0.121
Breuer et al.72 260 Serology Germany 1996 0.392 0.606 0.194
Asaka et al.73 109 Serology Japan 1995 0.743 0.224 0.022
Holtmann et al.74 180 Serology Germany 1994 0.317 0.606 0.186
Graham et al.75 485 13C Urea
breath test
USA 1991 0.502 0.55 0.227
The table includes only data from countries with a gross domestic product >US$ 17 000 (purchasing power parity
(PPP) adjusted).
Table 1. Studies reporting of H. pyloriprevalence (proportion of subjects with H. pyloriinfection) and WHO data on body
mass index (proportion of overweight (BMI 2530) and obese (BMI >30) subjects in the various countries
Study
Sample
size Methods Country Year
Prevalence
H. pylori
Prevalence
overweight
Prevalence
obesity
Shapira et al.31 100 Serology Italy 2011 0.3 0.44 0.098
Peleteiro et al34 649 Serology Portugal 2011 0.85 0.535 0.142
8/11/2019 Helicobacter Pylori Journal Article
5/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 5
Lane et al.7 10 537 UBT UK 2011 0.155 0.61 0.227
Adamu et al.33 5229 Serology Germany 2011 0.4984 0.665 0.129
Whiteman et
al.351346 Serology Australia 2010 0.23 0.49 0.164
Telaranta-Keerie
et al.364256 Serology,
ELISA
Finland 2010 0.19 0.488 0.157
Sasazuki et al.37 494 Serology Japan 2010 0.751 0.232 0.031
Salomaa-
Rasanen et al.38504 Serology Finland 1994 0.36 0.42 0.106
Risch et al.32 690 Serology;
ELISA
USA 2010 0.17391 0.669 0.339
Kawai et al.39 418 Serology,
IgG
Japan 2010 0.337 0.232 0.031
Fullerton et al.40 2437 Serology England 2009 0.264 0.61 0.227
Moujaber et al.41 2413 Serology Australia 2002 0.151 0.462 0.151
De Bastiani et
al.43104 Urea breath
test
Italy 2008 0.54 0.44 0.098
Stettin et al.44 563 Stool
samples
Germany 2007 0.21 0.665 0.129
Sanchez
Ceballos et al.45481 Urea breath
test
Spain 2007 0.603 0.534 0.156
Naja et al.46 1306 Serology Canada 2007 0.231 0.591 0.231
Sharara et al.47 104
(males
only)
Serology Italy 2006 0.683 0.44 0.098
Macenlle Garcia
et al.48383 Urea breath
test
Spain 2006 0.691 0.534 0.156
Cardenas et al.49 7462 Serology USA 2000 0.271 0.583 0.307
Kuepper-Nybelen
et al.496545 Serology Germany 1999 0.407 0.60 0.203
Ioannou et al.26 3130 Serology USA 2005 0.35 0.669 0.339
Ang et al.50 595 Serology Japan 2005 0.463 0.325 0.069
Cho et al.5 7003 Serology USA 2005 0.38 0.669 0.339
Simon et al.51 6746 Serology USA 2003 0.32 0.545 0.307
Robertson et
al.52500 Serology Australia 2003 0.32 0.49 0.164
Nishise et al.53 695 Serology Japan 2003 0.6 0.232 0.031
8/11/2019 Helicobacter Pylori Journal Article
6/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 6
Iszlai et al.54 756 ELISA Hungary 2000 0.586 0.532 0.177
Moayyedi et
al.558429 13C urea
breath test
England 2002 0.276 0.61 0.227
Bode et al.56 474 Serology Germany 2001 0.308 0.606 0.194
Bazzoli et al.57 1533 13C Urea
breath test
Italy 2001 0.679 0.42 0.085
Rosenstock etal.58
2527 Serology Denmark 19831994
0.247 0.417 0.094
Everhart et al.59 5465 Serology USA 1988
1991
0.325 0.55 0.227
Russo et al.60 2598 Serology Italy 1995
1997
0.45 0.385 0.064
Peach et al.61 324 Serology Australia 1999 0.3 0.573 0.193
Collett et al.62 1060 Serology Australia 1999 0.24 0.573 0.193
Senra-Varel etal.63
332 Serology Spain 1998 0.43 0.36 0.121
Martin de Argila
et al.64301 Serology UK 1998 0.522 0.669 0.11
Lin et al.65 273 Serology Australia 1998 0.38 0.598 0.193
Dite et al.66 309 Serology Czech
republic
1998 0.588 0.46 0.114
Babus et al.67 456 Serology Croatia 1998 0.5105 0.644 0.231
Rodrigo Saez etal.68
480 Serology Spain 1997 0.492 0.488 0.121
Peach et al.61 217 Serology Australia 1995 0.306 0.573 0.193
Murray et al.69 4742 Serology Northern
Ireland
1997 0.505 0.669 0.11
Babus et al.70 3082 Serology Croatia 1997 0.604 0.644 0.231
Martin-de-Argila
et al.71381 Serology Spain 1996 0.53 0.488 0.121
Breuer et al.72
260 Serology Germany 1996 0.392 0.606 0.194
Asaka et al.73 109 Serology Japan 1995 0.743 0.224 0.022
Holtmann et al.74 180 Serology Germany 1994 0.317 0.606 0.186
Graham et al.75 485 13C Urea
breath test
USA 1991 0.502 0.55 0.227
The table includes only data from countries with a gross domestic product >US$ 17 000 (purchasing power parity
(PPP) adjusted).
Overweight and Obesity Prevalence
8/11/2019 Helicobacter Pylori Journal Article
7/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 7
Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. Based upon
the WHO definitions, we used the body mass index (BMI). It is defined as a person's weight in kilograms divided by
the square of his height in metres (kg/m2). A BMI greater than or equal to 25 is overweight and a BMI greater than or
equal to 30 defines obesity.[16]
Data Analysis
Mean prevalence rates for the different countries and different methods for the assessment were calculated. In a
second step, the correlations between the H. pyloriprevalence and overweight and obesity rates in the respective
geographical regions were calculated. To ensure that the association between H. pyloriand obesity/overweight
prevalence rates were not due to an effect of GDP per capita an additional partial correlation analysis that removed
the effect of the purchase power parity (PPP) adjusted GDP per capita was performed. All analysis statistical
analysis were done utilising spss version 22.
Results
Forty-nine studies with a total of 99,463 subjects were identified ( ). There were significant differences in H. pylori
prevalence rates for different countries. The lowest H. pylorirates were reported from Australia (15.1%), the highest fo
Portugal (85%) with a mean H. pylorirate of 41.9%. Similarly, there was considerable variability in prevalence rates
for overweight and obesity ranging from 22.4 to 66.9% (mean 51.9) and 2.2 to 33.9% (mean 16.2), respectively. As
shown in Figure 1 the prevalence of obesity and overweight were inversely and significantly ( r= 0.43, P< 0.01 and r= 0.292, P< 0.05) correlated with the prevalence of H. pyloriinfection (Figure 1). The association between H. pylori
prevalence and overweight or obesity remained significant after adjusting for GDP per capita (r= 0.352, P< 0.02 and
r= 0.291, P< 0.05). Interestingly, GDP per capita and H. pyloriprevalence were inversely correlated (r= 0.387, P
< 0.01).
Table 1. Studies reporting of H. pyloriprevalence (proportion of subjects with H. pyloriinfection) and WHO data on body
mass index (proportion of overweight (BMI 2530) and obese (BMI >30) subjects in the various countries
Study
Sample
size Methods Country Year
Prevalence
H. pylori
Prevalence
overweight
Prevalence
obesity
Shapira et al.31 100 Serology Italy 2011 0.3 0.44 0.098
Peleteiro et al34 649 Serology Portugal 2011 0.85 0.535 0.142
Lane et al.7 10 537 UBT UK 2011 0.155 0.61 0.227
Adamu et al.33 5229 Serology Germany 2011 0.4984 0.665 0.129
Whiteman et
al.351346 Serology Australia 2010 0.23 0.49 0.164
Telaranta-Keerie
et al.
364256 Serology,
ELISA
Finland 2010 0.19 0.488 0.157
Sasazuki et al.37 494 Serology Japan 2010 0.751 0.232 0.031
Salomaa-
Rasanen et al.38504 Serology Finland 1994 0.36 0.42 0.106
Risch et al.32 690 Serology;
ELISA
USA 2010 0.17391 0.669 0.339
Kawai et al.39 418 Serology,
IgG
Japan 2010 0.337 0.232 0.031
8/11/2019 Helicobacter Pylori Journal Article
8/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 8
Fullerton et al.40 2437 Serology England 2009 0.264 0.61 0.227
Moujaber et al.41 2413 Serology Australia 2002 0.151 0.462 0.151
De Bastiani et
al.43104 Urea breath
test
Italy 2008 0.54 0.44 0.098
Stettin et al.44 563 Stool
samples
Germany 2007 0.21 0.665 0.129
SanchezCeballos et al.45
481 Urea breathtest
Spain 2007 0.603 0.534 0.156
Naja et al.46 1306 Serology Canada 2007 0.231 0.591 0.231
Sharara et al.47 104
(males
only)
Serology Italy 2006 0.683 0.44 0.098
Macenlle Garcia
et al.48383 Urea breath
test
Spain 2006 0.691 0.534 0.156
Cardenas et al.49 7462 Serology USA 2000 0.271 0.583 0.307
Kuepper-Nybelen
et al.496545 Serology Germany 1999 0.407 0.60 0.203
Ioannou et al.26 3130 Serology USA 2005 0.35 0.669 0.339
Ang et al.50 595 Serology Japan 2005 0.463 0.325 0.069
Cho et al.5 7003 Serology USA 2005 0.38 0.669 0.339
Simon et al.51 6746 Serology USA 2003 0.32 0.545 0.307
Robertson et
al.52
500 Serology Australia 2003 0.32 0.49 0.164
Nishise et al.53 695 Serology Japan 2003 0.6 0.232 0.031
Iszlai et al.54 756 ELISA Hungary 2000 0.586 0.532 0.177
Moayyedi et
al.558429 13C urea
breath test
England 2002 0.276 0.61 0.227
Bode et al.56 474 Serology Germany 2001 0.308 0.606 0.194
Bazzoli et al.57 1533 13C Urea
breath test
Italy 2001 0.679 0.42 0.085
Rosenstock et
al.582527 Serology Denmark 1983
1994
0.247 0.417 0.094
Everhart et al.59 5465 Serology USA 1988
1991
0.325 0.55 0.227
Russo et al.60 2598 Serology Italy 1995
1997
0.45 0.385 0.064
Peach et al.61 324 Serology Australia 1999 0.3 0.573 0.193
Collett et al.62 1060 Serology Australia 1999 0.24 0.573 0.193
8/11/2019 Helicobacter Pylori Journal Article
9/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 9
Senra-Varel et
al.63332 Serology Spain 1998 0.43 0.36 0.121
Martin de Argila
et al.64301 Serology UK 1998 0.522 0.669 0.11
Lin et al.65 273 Serology Australia 1998 0.38 0.598 0.193
Dite et al.66 309 Serology Czech
republic
1998 0.588 0.46 0.114
Babus et al.67 456 Serology Croatia 1998 0.5105 0.644 0.231
Rodrigo Saez et
al.68480 Serology Spain 1997 0.492 0.488 0.121
Peach et al.61 217 Serology Australia 1995 0.306 0.573 0.193
Murray et al.69 4742 Serology Northern
Ireland
1997 0.505 0.669 0.11
Babus et al.70 3082 Serology Croatia 1997 0.604 0.644 0.231
Martin-de-Argilaet al.71
381 Serology Spain 1996 0.53 0.488 0.121
Breuer et al.72 260 Serology Germany 1996 0.392 0.606 0.194
Asaka et al.73 109 Serology Japan 1995 0.743 0.224 0.022
Holtmann et al.74 180 Serology Germany 1994 0.317 0.606 0.186
Graham et al.75 485 13C Urea
breath test
USA 1991 0.502 0.55 0.227
The table includes only data from countries with a gross domestic product >US$ 17 000 (purchasing power parity
(PPP) adjusted).
8/11/2019 Helicobacter Pylori Journal Article
10/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 10
Figure 1.
Association between the prevalence of H. pylori(%) and prevalence of obesity in countries with a gross domestic
product (GDP) per capita >US$ 25 000 (purchasing power parity (PPP) adjusted). The prevalence of obesity in a givenpopulation is inversely correlated with the H. pyloriprevalence in the same population (r= 0.46, P< 0.01).
Discussion
The key finding of this study is a striking inverse association between the H. pyloriprevalence in various countries and
the prevalence of overweight or obesity in these countries. This finding is consistent with previous observations in
controlled trials that after successful H. pylorieradication patients experience a significant increase in weight that
was not observed in control subjects who had placebo instead of H. pylorieradication.[7]Along the same lines, a
cohort study observed that children who were never infected with H. pylorior cleared the infection grew significantly
faster (gained weight) than those with persistent H. pyloriinfection.[18]Another intervention study demonstrated in H.
pylori-infected children growth retardation and low serum acylated ghrelin. [16]In these children, H. pylorieradication
restored ghrelin levels and increased body weight gains and growth.
Weight gain following H. pylorieradication could be attributed to improvement of postprandial symptoms such as
early satiety that may affect some people. However, the efficiency of H. pylorieradication with regard to symptoms is
very small[17]and other large well controlled studies were not able to demonstrate any effect. [19]More importantly, a
positive trial[6]conducted in a geographical region that had a high peptic ulcer prevalence and long waiting times for
endoscopic procedures suggests that the beneficial effect might be due to undiagnosed peptic ulcer disease. There is
also some evidence that H. pylorimay protect against symptoms of gastro-oesophageal reflux while obesity is a risk
factor for the manifestation of GERD. [20]Thus, it might be speculated that the manifestation of GERD symptoms
8/11/2019 Helicobacter Pylori Journal Article
11/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 1
affects behaviour and thus may have an impact on weight gain.
Among other factors, the hormone ghrelin is relevant for the regulation of appetite and food intake.[21]Interestingly, in
one study, plasma ghrelin increased profoundly in asymptomatic subjects after H. pyloricure.[22]This could lead to
increased appetite and consequently weight gain, and contribute to the increasing obesity seen in Western
populations where H. pyloriprevalence is low. Interestingly, other studies have shown that circulating meal-associated
leptin and ghrelin levels change significantly after H. pylorieradication, providing further direct evidence that H. pylori
colonisation is involved in ghrelin and leptin regulation, with consequent effects on body morphometry. [23]In another
study of 156 patients, who were undergoing laparoscopic vertical-banded gastroplasty for obesity, the density ofghrelin-positive cells was significantly lower for H. pylori-infected patients. Moreover, there was a significant stepwise
decrease in density of ghrelin-positive cells, with progression of histological severity of chronic inflammation,
neutrophil activity and glandular atrophy in the corpus.[24]H. pyloriinfection was also associated with a reduction in
circulating ghrelin levels independent of sex and BMI.[25]In contrast, in a cohort study with nearly 7000 subjects, H.
pyloriseropositivity and CagA antibody status were not associated with body mass index or fasting serum leptin
level.[26]
It might be argued that the inverse relation between H. pyloriand obesity that was found in our study is mediated by
the development status of the various countries which is reflected by the GDP. In our study, we have only included
countries with a (PPP adjusted) GDP per capita >US$ 25 000 to ensure that only developed countries were included.
In addition, in a separate analysis on the association between H. pyloriand the prevalence of overweight and obesity,we even adjusted for the GDP per capita in a partial correlation analysis. Even after this adjustment, the association
between H. pyloriand overweight/obesity remained significant across these developed countries. Thus, our data
clearly support the assumption that the association is not simply mediated by the income or the development status
of the populations included in this analysis.
While our data may suggest that the decrease in H. pyloriprevalence observed in many countries in recent decades
could be a contributing factor to the obesity endemic of the Western world, our study cannot rule out that other
factors that are correlated with the risk of a H. pyloriinfection are causal for the observed association. Indeed this
ecological study does not provide individual-level analysis. This can be seen as an advantage since an ecological
study might not be affected by some of the biases that may affect individual-level analysis. However, there are other
potential limitations such as ecological fallacy of the ecological approach that require a careful interpretation of the
data. In an ecologic study, the correlation between individual variables is deduced from the correlation of the variables
collected for the group to which those individuals belong. As a consequence, the correlation of aggregate quantities
may not be equal to the correlation of individual quantities. On the other hand, the ecological correlation (correlation o
aggregate quantities) may avoid specific selection biases (e.g. the patient cohorts may have received antibiotic
treatment for the management of obesity related diseases that may have affected the H. pylroistatus). It also needs
to be considered that there might be a temporal association between H. pyloriand obesity. i.e. while H. pylori
decreases over time, there is a parallel increase of obesity. However, it is unlikely that this effect is the explanation
for our results since during the time period between 1991 (oldest study) and 2011 (most recent study included) there
was no significant reduction of the H. pyloriprevalence over time (P> 0.20). Thus, a temporal association is unlikely
to explain the link between H. pyloriand obesity. Another potential error could be some kind of selection bias.However, a very comprehensive review of the published literature plus strict inclusion criteria should help to avoid this
error. It is important in this context to note that independent of our study other case control studies found very similar
results.[3,4]
However, other potential factors need to be considered. e.g. the gastrointestinal microbiome might be different in
subjects with or without H. pyloriinfection. Subjects with an H. pyloriinfection might have been exposed to
substantially more bacteria that ultimately may colonise the gastrointestinal mucosa. Thus subjects with H. pylori
infection may have been exposed to more bacteria as compared topylori-negative subject and thus may have a
different gastrointestinal microbiome. In addition, the patient's gastrointestinal microbiome may respond to antibiotic
therapy.[27]Thus while this ecological study clearly supports a link between H. pyloriand obesity it cannot be
8/11/2019 Helicobacter Pylori Journal Article
12/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 12
excluded that this is an indirect relationship. It might not be the H. pyloriinfection but other factors linked to H. pylori
that are causal for the observed association between H. pyloriand obesitas. Thus the role that the gastrointestinal
microbiome may play needs to be properly addressed. It is well established that there is an interplay between diet,
microbiome and health.[28]Recent evidence suggests that the gut microbiome may be related to the development of
obesity. This includes evidence of associations between obesity phenotypes and microbial class representation in
the gut[29]although further studies are needed. Studies looking at the effects of eradication treatment for H. pylori
infections on the intest inal microflora[27,30]have been plagued by methodological weakness and more research is
needed in order to fully understand the role that the microbiome may play in the observed relationship between
decreasing H. pyloriprevalence and the increasing rate of overweight/obesity.
While this study has several strengths including the focus on developed countries to avoid potential confounders, it
should be noted that the same obesity epidemic is taking place in developing countries[14]and not necessarily driven
by changes of H. pyloriprevalence. As we conducted an ecological study, we were not able to provide individual-level
analysis and it is therefore critical to carefully interpret the data. However, with regard to the association between H.
pyloriand obesity besides direct effects of the H. pylori infect ionalso potential confounders such as the influence of
antibiotic use and the gastrointestinal microbiome should be examined in future studies in this area.
In summary, while previous data already have suggested that weight gain may occur after antibiotic therapy targeting
H. pylorieradication, our data demonstrate that the prevalence of gastric H. pyloricolonisation in various countries is
inversely related to the prevalence of obesity. The obesity endemic observed in the Western world thus may partly belinked to a reduction of the prevalence of H. pylori. Alternatively, it might be speculated that hygiene factors that
favour a high H. pyloriprevalence have a protective role with regard to the manifestation of obesity e.g. via effects on
the gastrointestinal microbiome. Thus the H. pyloriprevalence could be a marker for these protective factors. While
these observations require further studies, they may provide important novel insights into the mechanisms that are
relevant for the obesity endemic in the developed world.
References
1. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nature reviews.
Endocrinology2013; 9: 1327.
2. Mascie-Taylor CG, Karim E. The burden of chronic disease. Science2003; 302: 19212.
3. Wu MS, Lee WJ, Wang HH, et al.A case-control study of association of Helicobacter pyloriinfection with
morbid obesity in Taiwan.Arch Intern Med2005; 165: 15525.
4. Ekesbo R, Nilsson PM, Lindholm LH, et al.Combined seropositivity for H. pyloriand C. pneumoniaeis
associated with age, obesity and social factors. J Cardiovasc Risk2000; 7: 1915.
5. Cho I, Blaser MJ, Francois F, et al. Helicobacter pyloriand overweight status in the United States: data from
the Third National Health and Nutrition Examination Survey.Am J Epidemiol2005; 162: 57984.
6. Kamada T, Sugiu K, Haruma K. Development of obesity and hyperlipidemia after eradication of Helicobacter
pylori. Nihon Rinsho2005; 63(Suppl. 11): 5368.
7. Lane JA, Murray LJ, Harvey IM, et al.Randomised clinical trial: Helicobacterpylorieradication is associated
with a significantly increased body mass index in a placebo-controlled study.Aliment Pharmacol Ther2011;
33: 9229.
8. Bassaganya-Riera J, Dominguez-Bello MG, Kronsteiner B, et al. Helicobacter pyloricolonization ameliorates
glucose homeostasis in mice through a PPAR gamma-dependent mechanism. PLoS ONE2012; 7: e50069.
9. Boone-Heinonen J, Gordon-Larsen P, Kiefe CI, et al.Fast food restaurants and food stores: longitudinal
8/11/2019 Helicobacter Pylori Journal Article
13/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 13
associations with diet in young to middle-aged adults: the CARDIA study. Arch Intern Med2011; 171: 1162
70.
10. Zillikens MC, van Meurs JB, Rivadeneira F, et al.SIRT1 genetic variation is related to BMI and risk of obesity.
Diabetes2009; 58: 282834.
11. Singh M, Kirchengast S. Obesity prevalence and nutritional habits among Indian women: a comparison
between Punjabi women living in India and Punjabi migrants in Vienna, Austria. Anthropologischer Anzeiger;
Bericht uber die biologisch-anthropologische Literatur2011; 68: 23951.
12. Parr CL, Batty GD, Lam TH, et al.Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies
Collaboration: pooled analyses of 424,519 participants. Lancet Oncol2010; 11: 74152.
13. Agarwal AK, Jain V, Singla S, et al.Prevalence of non-alcoholic fatty liver disease and its correlation with
coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India2011; 59: 3514.
14. Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol2006; 35: 939.
15. Nakajima S, Nishiyama Y, Yamaoka M, et al.Changes in the prevalence of Helicobacter pyloriinfection and
gastrointestinal diseases in the past 17 years. J Gastroenterol Hepatol2010; 25 (Suppl. 1): S99110.
16. Yang YJ, Sheu BS, Yang HB, et al.Eradication of Helicobacter pylori increases childhood growth and serum
acylated ghrelin levels. World J Gastroenterol2012; 18: 267481.
17. McColl K, Murray L, El-Omar E, et al.Symptomatic benefit from eradicating Helicobacter pyloriinfection in
patients with nonulcer dyspepsia. N Engl J Med1998; 339: 186974.
18. Mera RM, Bravo LE, Goodman KJ, Yepez MC, Correa P. Long-term effects of clearing Helicobacter pylori on
growth in school-age children. Pediatr Infect Dis J2012; 31: 2636.
19. Blum AL, Talley NJ, O'Morain C, et al.Lack of effect of treating Helicobacter pyloriinfection in patients with
nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY)Study Group. N Engl J Med1998; 339: 187581.
20. Breckan RK, Paulssen EJ, Asfeldt AM, Mortensen L, Straume B, Florholmen J. The impact of body mass
index and Helicobacter pylori infection on gastrooesophageal reflux symptoms: a population-based study in
Northern Norway. Scand J Gastroenterol2009; 44: 10606.
21. Uchida A, Zigman JM, Perello M. Ghrelin and eating behavior: evidence and insights from genetically-modified
mouse models. Front Neurosci2013; 7: 121.
22. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS. Plasma ghrelin following cure of Helicobacter pylori. Gu
2003; 52: 63740.
23. Francois F, Roper J, Joseph N, et al.The effect of H. pylori eradication on meal-associated changes in plasma
ghrelin and leptin. BMC Gastroenterol2011; 11: 37.
24. Liew PL, Lee WJ, Lee YC, et al.Gastric ghrelin expression associated with Helicobacter pyloriinfection and
chronic gastritis in obese patients. Obes Surg2006; 16: 6129.
25. Shiotani A, Miyanishi T, Uedo N, et al. Helicobacter pyloriinfection is associated with reduced circulating
ghrelin levels independent of body mass index. Helicobacter2005; 10: 3738.
8/11/2019 Helicobacter Pylori Journal Article
14/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 14
26. Ioannou GN, Weiss NS, Kearney DJ. Is Helicobacter pyloriseropositivity related to body mass index in the
United States?Aliment Pharmacol Ther2005; 21: 76572.
27. Adamsson I, Nord CE, Lundquist P, et al.Comparative effects of omeprazole, amoxycillin plus metronidazole
versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in
Helicobacter pyloriinfected patients. J Antimicrob Chemother1999; 44: 62940.
28. Korpela K, Flint HJ, Johnstone AM, et al.Gut microbiota signatures predict host and microbiota responses to
dietary interventions in obese individuals. PLoS ONE2014; 9: e90702.
29. Ley RE, Turnbaugh PJ, Klein S, et al.Microbial ecology: human gut microbes associated with obesity. Nature
2006; 444: 10223.
30. Buhling A, Radun D, Muller WA, et al.Influence of anti-Helicobacter tripletherapy with metronidazole,
omeprazole and clarithromycin on intestinal microflora.Aliment Pharmacol Ther2001; 15: 144552.
31. Shapira Y, Poratkatz BS, Gilburd B, et al.Geographical differences in autoantibodies and anti-infectious
agents antibodies among healthy adults. Clin Rev Allergy Immunol2011 [Epub ahead of print].
32. Risch HA, Yu H, Lu L, et al.ABO blood group, Helicobacter pyloriseropositivity, and risk of pancreatic
cancer: a case-control study. J Natl Cancer Inst2010; 102: 5025.
33. Adamu MA, Weck MN, Rothenbacher D, et al.Incidence and risk factors for the development of chronic
atrophic gastritis: five year follow-up of a population-based cohort study. Int J Cancer2011; 128: 16528.
34. Peleteiro B, Lopes C, Figueiredo C, et al.Salt intake and gastric cancer risk according to Helicobacter pylori
infection, smoking, tumour site and histological type. Br J Cancer2011; 104: 198207.
35. Whiteman DC, Parmar P, Fahey P, et al.Association of Helicobacter pyloriinfection with reduced risk for
esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology2010; 139: 7383
36. Telaranta-Keerie A, Kara R, Paloheimo L, et al.Prevalence of undiagnosed advanced atrophic corpus gastritisin Finland: an observational study among 4,256 volunteers without specific complaints. Scand J Gastroenterol
2010; 45: 103641.
37. Sasazuki S, Inoue M, Sawada N, et al.Plasma levels of C-reactive protein and serum amyloid A and gastric
cancer in a nested case-control study: Japan Public Health Center-based prospective study. Carcinogenesis
2010; 31: 7128.
38. Salomaa-Rasanen A, Kosunen TU, Aromaa AR, et al.A "screen-and-treat" approach for Helicobacter pylori
infection: a population-based study in Vammala, Finland. Helicobacter2010; 15: 2837.
39. Kawai T, Yamamoto K, Fukuzawa M, et al. Helicobacter pyloriinfection and reflux esophagitis in young andmiddle-aged Japanese subjects. J Gastroenterol Hepatol2010; 25(Suppl. 1): S805.
40. Fullerton D, Britton JR, Lewis SA, et al. Helicobacter pyloriand lung function, asthma, atopy and allergic
diseasea population-based cross-sectional study in adults. Int J Epidemiol2009; 38: 41926.
41. Moujaber T, MacIntyre CR, Backhouse J, Gidding H, Quinn H, Gilbert GL. The seroepidemiology of
Helicobacter pylori infection in Australia. Int J Infect Dis2008; 12: 5004.
42. Kuepper-Nybelen J, Thefeld W, Rothenbacher D, et al.Patterns of alcohol consumption and Helicobacterpylor
infection: results of a population-based study from Germany among 6545 adults.Aliment Pharmacol Ther
8/11/2019 Helicobacter Pylori Journal Article
15/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 15
2005; 21: 5764.
43. De Bastiani R, Gabrielli M, Ubaldi E, et al.High prevalence of Cag-A positive H. pyloristrains in ischemic
stroke: a primary care multicenter study. Helicobacter2008; 13: 2747.
44. Stettin D, Waldmann A, Wolters M, et al.Infection with Helicobacter pylori outcome of a cross-sectional
investigation. Dtsch Med Wochenschr2007; 132: 267782.
45. Sanchez Ceballos F, Taxonera Samso C, Garcia Alonso C, et al.Prevalence of Helicobacter pyloriinfection in
the healthy population of Madrid (Spain). Rev Esp Enferm Dig2007; 99: 497501.
46. Naja F, Kreiger N, Sullivan T. Helicobacter pyloriinfection in Ontario: prevalence and risk factors. Can J
Gastroenterol2007; 21: 5016.
47. Sharara AI, Abdul-Baki H, ElHajj I, et al.Association of gastroduodenal disease phenotype with ABO blood
group and Helicobacter pylorivirulence-specific serotypes. Dig Liver Dis2006; 38: 82933.
48. Macenlle Garcia R, Gayoso Diz P, Sueiro Benavides RA, et al.Prevalence of Helicobacter pyloriinfection in
the general adult population of the province of Ourense. Rev Esp Enferm Dig2006; 98: 2418.
49. Cardenas VM, Mulla ZD, Ortiz M, et al.Iron deficiency and Helicobacter pyloriinfection in the United States.Am J Epidemiol2006; 163: 12734.
50. Ang TL, Fock KM, Dhamodaran S, et al.Racial differences in Helicobacter pylori, serum pepsinogen and
gastric cancer incidence in an urban Asian population. J Gastroenterol Hepatol2005; 20: 16039.
51. Simon JA, Hudes ES, Perez-Perez GI. Relation of serum ascorbic acid to Helicobacter pyloriserology in US
adults: the Third National Health and Nutrition Examination Survey. J Am Coll Nutr2003; 22: 2839.
52. Robertson MS, Cade JF, Savoia HF, et al. Helicobacter pyloriinfection in the Australian community: current
prevalence and lack of association with ABO blood groups. Intern Med J2003; 33: 1637.
53. Nishise Y, Fukao A, Takahashi T. Risk factors for Helicobacter pyloriinfection among a rural population in
Japan: relation to living environment and medical history. J Epidemiol2003; 13: 26673.
54. Iszlai E, Kiss E, Toldy E, et al.Seroprevalence of Helicobacter pyloriinfection and anti-CagA positivity in the
county Szabolcs-Szatmar-Bereg. Orv Hetil2003; 144: 17138.
55. Moayyedi P, Axon AT, Feltbower R, et al.Relation of adult lifestyle and socioeconomic factors to the
prevalence of Helicobacter pyloriinfection. Int J Epidemiol2002; 31: 62431.
56. Bode G, Hoffmeister A, Koenig W, et al.Characteristics of differences in Helicobacter pyloriserology and
13Curea breath-testing in an asymptomatic sample of blood donors. Scand J Clin Lab Invest2001; 61: 6038
57. Bazzoli F, Palli D, Zagari RM, et al.The Loiano-Monghidoro population-based study of Helicobacter pylori
infection: prevalence by 13C-urea breath test and associated factors.Aliment Pharmacol Ther2001; 15: 1001
7.
58. Rosenstock S, Jorgensen T, Andersen L, et al.Seroconversion and seroreversion in IgG antibodies to
Helicobacter pylori: a serology based prospective cohort study. J Epidemiol Community Health2000; 54:
44450.
59. Everhart JE, Kruszon-Moran D, Perez-Perez GI, et al.Seroprevalence and ethnic differences in Helicobacter
8/11/2019 Helicobacter Pylori Journal Article
16/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
http://www.medscape.com/viewarticle/827210_print 16
Aliment Pharmacol Ther. 2014;40(1):24-31. 2014 Blackwell Publishing
pyloriinfection among adults in the United States. J Infect Dis2000; 181: 135963.
60. Russo A, Eboli M, Pizzetti P, et al.Determinants of Helicobacter pyloriseroprevalence among Italian blood
donors. Eur J Gastroenterol Hepatol1999; 11: 86773.
61. Peach HG, Bath NE, Farish SJ. Helicobacter pyloriinfection is not a correlate of plasma fibrinogen in the
Australian population. Clin Lab Haematol1999; 21: 413.
62. Collett JA, Burt MJ, Frampton CM, et al.Seroprevalence of Helicobacter pyloriin the adult population of
Christchurch: risk factors and relationship to dyspeptic symptoms and iron studies. N Z Med J1999; 112:
2925.
63. Senra-Varela A, Lopez-Saez JB, Gomez-Biondi V. Prevalence of Helicobacter pyloriinfection in two Spanish
regions with different incidence of gastric cancer. Eur J Epidemiol1998; 14: 4914.
64. Martin de Argila C, Boixeda D, Valdezate S, et al.ABO blood groups, rhesus factor and Helicobacter pylori.
Rev Esp Enferm Dig1998; 90: 2638.
65. Lin SK, Lambert JR, Nicholson L, et al.Prevalence of Helicobacter pyloriin a representative Anglo-Celtic
population of urban Melbourne. J Gastroenterol Hepatol1998; 13: 50510.
66. Dite P, Hep A, Dolina J, et al.Prevalence of Helicobacter pyloriinfection in the Czech Republicthe South
Moravia Region. Vnitr Lek1998; 44: 1324.
67. Babus V, Strnad M, Presecki V, et al.Helicobacter pyloriand gastric cancer in Croatia. Cancer Lett1998; 125
915.
68. Rodrigo Saez L, Riestra Menendez S, Fernandez Rodriguez E, et al.Epidemiological study of the prevalence
of Helicobacter pyloriinfection in the general population in Asturias, Spain. Rev Esp Enferm Dig1997; 89:
51122.
69. Murray LJ, McCrum EE, Evans AE, et al.Epidemiology of Helicobacter pyloriinfection among 4742 randomlyselected subjects from Northern Ireland. Int J Epidemiol1997; 26: 8807.
70. Babus V, Presecki V, Katicic M, et al.Distribution of Helicobacter pyloriinfection in the adult population of
Croatia. Lijec Vjesn1997; 119: 13942.
71. Martin-de-Argila C, Boixeda D, Canton R, et al. Helicobacter pyloriinfection in a healthy population in Spain.
Eur J Gastroenterol Hepatol1996; 8: 11658.
72. Breuer T, Sudhop T, Hoch J, et al.Prevalence of and risk factors for Helicobacter pyloriinfection in the western
part of Germany. Eur J Gastroenterol Hepatol1996; 8: 4752.
73. Asaka M, Kato M, Kudo M, et al.Relationship between Helicobacter pyloriinfection, atrophic gastritis and
gastric carcinoma in a Japanese population. Eur J Gastroenterol Hepatol1995; 7(Suppl. 1): S710.
74. Holtmann G, Goebell H, Holtmann M, et al.Dyspepsia in healthy blood donors. Pattern of symptoms and
association with Helicobacter pylori. Dig Dis Sci1994; 39: 10908.
75. Graham DY, Malaty HM, Evans DG, et al.Epidemiology of Helicobacter pyloriin an asymptomatic population
in the United States. Effect of age, race, and socioeconomic status. Gastroenterology1991; 100: 1495501.
8/11/2019 Helicobacter Pylori Journal Article
17/17
9/11/2014 http://www.medscape.com/viewarticle/827210_pr int is not avai lable
Recommended